

**RESPONSE/ARGUMENT**


This is in response to the Official Action of February 25, 2005 for the above-captioned application. Claims 1 to 5 are pending in the application. Claims 1 and 4 were amended and claims 6 to 7 were cancelled. Claims 8 to 11 were cancelled in a previous response. Claims 1 to 4 were amended to try to correspond to the elected invention searched and examined on page 3 of the Office Action. Please note, for example, that X<sup>1</sup> and X<sup>2</sup> may be slightly broader than requested in the Office Action, however, the matter retained primarily relates to alkyl groups and should be covered by any search conducted by the Examiner. Applicants respectfully request that the Examiner check the amendments to Claims 1 and 4.

In view of the foregoing remarks and amendments, allowance of all pending claims in the application is respectfully requested.

No fee is believed due for this submission. If any fee is required to cover this submission, please charge the appropriate fee to Pfizer Deposit Account No. 16-1445.

Respectfully submitted,

Date: May 25, 2005

  
\_\_\_\_\_  
James A. Jubinsky  
Attorney for Applicant(s)  
Reg. No. 42,700

Pfizer Inc  
Patent Department  
150 East 42nd Street – 5<sup>th</sup> Floor  
New York, NY 10017-5755  
(212) 733-0634